ACR Convergence 2021

医学 托法替尼 类风湿性关节炎 Janus激酶抑制剂 狼牙棒 阿达木单抗 内科学 依那西普 危险系数 不利影响 外科 置信区间 心肌梗塞 传统PCI
作者
Helen Brooks,Anna Clark,Heather Van Epps
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:4 (1): e18-e19
标识
DOI:10.1016/s2665-9913(21)00397-0
摘要

The ORAL Surveillance study is a phase 4, open-label, safety trial designed to assess whether adverse effects of the Janus kinase (JAK) inhibitor tofacitinib were comparable (ie, non-inferior) to TNF inhibitors with regard to major adverse cardiovascular events (MACE) and malignancies in high-risk patients with rheumatoid arthritis. Patients with moderate-to-severe rheumatoid arthritis unresponsive to methotrexate, aged 50 years or older, with one or more additional cardiovascular risk factors were randomly assigned (1:1:1) to receive tofacitinib 5 mg (n=1455) or 10 mg (n=1456) twice daily, or a TNF inhibitor (n=1451; adalimumab 40 mg every other week in North America or etanercept 50 mg every week elsewhere); all patients continued taking methotrexate. The primary results of ORAL Surveillance were presented by Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA). Tofacitinib failed to show non-inferiority compared to TNF inhibitors for both MACE and malignancies (excluding non-melanoma skin cancer), with the upper limit of the 95% CI exceeding the non-inferiority margin of 1·8 for both outcomes (hazard ratio [HR] 1·33 [95% CI 0·91–1·94] for MACE and 1·48 [1·04–2·09] for malignancies). A post-hoc analysis of the risk factors for MACE in ORAL Surveillance was presented by Christina Charles-Schoeman (University of California Los Angeles, Los Angeles, CA, USA). Baseline factors including current smoking (HR 2·18 [95% CI 1·50–3·16]), aspirin use (2·11 [1·40–3·19]), age 65 years or older (1·81 [1·27–2·59]), and male sex (1·81 [1·25–2·61]) were identified as independent risk factors for MACE, irrespective of treatment assignment. In a post-hoc analysis presented by Jeffrey Curtis (University of Alabama at Birmingham, Birmingham, AL, USA), age 65 years or older (HR 2·04 [1·49–2·78]), current smoking (2·61 [1·79–3·81]), and past smoking (2·58 [1·72–3·73]) were identified as independent risk factors for malignancies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
葛根完成签到,获得积分10
刚刚
安静代荷完成签到,获得积分10
刚刚
哼哼哈嘿完成签到,获得积分10
刚刚
Bear完成签到 ,获得积分10
1秒前
逆流沙完成签到,获得积分10
1秒前
1秒前
工艺纯化小天才完成签到 ,获得积分10
2秒前
2秒前
欢快的芹菜完成签到,获得积分10
2秒前
2秒前
2秒前
Sakura完成签到,获得积分10
2秒前
gy完成签到 ,获得积分10
2秒前
3秒前
六六发布了新的文献求助10
3秒前
swimming完成签到,获得积分10
3秒前
资明轩完成签到,获得积分10
3秒前
3秒前
xl的应助被啵啵采纳,获得10
4秒前
专注的尔槐完成签到,获得积分10
4秒前
迷人皮卡丘完成签到 ,获得积分10
4秒前
Lindsay发布了新的文献求助10
5秒前
6秒前
XwX关注了科研通微信公众号
6秒前
SFGGFT发布了新的文献求助10
6秒前
6秒前
无心的蓝发布了新的文献求助10
7秒前
奇迹行者完成签到,获得积分10
7秒前
w2503完成签到,获得积分10
8秒前
8秒前
swimming发布了新的文献求助10
9秒前
Jasper的应助被贪玩的一曲采纳,获得10
10秒前
斯文败类的应助被Ccccc采纳,获得10
11秒前
12秒前
maxiaole的应助被科研通管家采纳,获得10
12秒前
情怀的应助被科研通管家采纳,获得10
12秒前
在水一方的应助被科研通管家采纳,获得10
12秒前
wanci的应助被科研通管家采纳,获得10
12秒前
12秒前
丘比特的应助被科研通管家采纳,获得50
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168163
求助须知:如何正确求助?哪些是违规求助? 9561243
关于积分的说明 21759855
捐赠科研通 7759477
什么是DOI,文献DOI怎么找? 3429959
关于科研通互助平台的介绍 2553757
邀请新用户注册赠送积分活动 2474496